Journey Medical (DERM) 10-Q2024 Q1 Quarterly report

Filed: 14 May 24, 4:46pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. freshman Avg

New words: annum, APA, ASU, ATM, compliance, Cosmetic, drawn, drew, erosion, FDCA, floor, foreign, function, glycopyrronium, goal, largely, LLC, Luxamend, Nasdaq, Overnight, owed, point, prepayment, reconciliation, regular, request, SOFR, submission, summitted, SWB, SWK, trailing, underlying, undrawn

Removed: accreted, acting, agent, agree, agreed, August, bank, borrowed, borrowing, calendar, capitalize, closed, comprised, conduct, convertible, coupon, curtailing, dated, decline, deductible, delaying, detailed, dilute, diminution, discontinuing, dispose, divert, East, equivalent, EWB, expanded, fifteen, final, fixed, foam, footnote, formed, glycoprronium, guarantee, headcount, higher, Identifiable, impacted, implemented, incur, initiative, Japan, Japanese, licensee, limited, line, manufacturing, Maruho, Meeting, Molecule, necessarily, occur, omitted, opinion, order, par, partner, platform, presented, previously, proprietary, provision, pursue, Rapifort, reach, relinquish, repaid, restrictive, revise, revolving, Riley, salesforce, security, setting, show, significantly, Stabilizing, strategy, sublicensee, supplemented, support, territory, topical, transferred, unencumbered, unfavorable, unit, West

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated DERM transcripts

DERM similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Claude Maraoui, President and Chief Executive Officer of Journey Medical Corporation (the “Company”), in compliance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that, to the best of my knowledge, the Company’s quarterly report on Form 10-Q for the period ended March 31, 2024 (the “Report”) filed with the Securities and Exchange Commission:

●

Fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

●

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

		/s/ Claude Maraoui
		Claude Maraoui
		President and Chief Executive Officer
		(Principal Executive Officer)
		May 14, 2024

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.